Far Infrared Therapy Inhibits Vascular Endothelial Inflammation via the Induction of Heme Oxygenase-1

July 1, 2008

Abstract

Objective—Survival of arteriovenous fistulas (AVFs) in hemodialysis patients is associated with both far infrared (FIR) therapy and length polymorphisms of the heme oxygenase-1 (HO-1) promoter. In this study, we evaluated whether there is an interaction between FIR radiation and HO-1 in regulating vascular inflammation.

Methods and Results—Treatment of cultured human umbilical vein endothelial cells (ECs) with FIR radiation stimulated HO-1 protein, mRNA, and promoter activity. HO-1 induction was dependent on the activation of the antioxidant responsive element/NF-E2-related factor-2 complex, and was likely a consequence of heat stress. FIR radiation also inhibited tumor necrosis factor-α-mediated expression of E-selectin, vascular cell adhesion molecule-1, intercellular cell adhesion molecule-1, monocyte chemoattractant protein-1, interleukin-8, and the cytokine-mediated adhesion of monocytes to ECs. The anti-inflammatory action of FIR was mimicked by bilirubin, and was reversed by the HO inhibitor, tin protoporphyrin-IX, or by the selective knockdown of HO-1. Finally, the anti-inflammatory effect of FIR was also observed in patients undergoing hemodialysis.

Conclusions—These results demonstrate that FIR therapy exerts a potent anti-inflammatory effect via the induction of HO-1. The ability of FIR therapy to inhibit inflammation may play a critical role in preserving blood flow and patency of AVFs in hemodialysis patients.

-Arterioscler Thromb Vasc Biol. 2008 April ; 28(4): 739–745.

Want to know more?



Contact us for more detail


Learn more
Questions to FIRAPY
August 19, 2026
A new study published in Cells has provided further insight into the molecular responses of arterial endothelial cells following far-infrared (FIR) irradiation.  The study, conducted by researchers from Gunma Paz University, Japan, investigated the effects of FIR on human femoral artery endothelial cells (HFAECs) using an integrated multi-omics approach combining transcriptomics, proteomics, and phosphoproteomics. FIR irradiation was delivered using the WSTM TY101F far-infrared therapy unit manufactured by WS Far Infrared Medical Technology.
FIRAPY at MEDICA 2026 | Innovative Care for Dialysis Patients
August 19, 2026
Meet FIRAPY at MEDICA 2026 in Düsseldorf, November 16–19. Visit Hall 16, Booth B03-2 to explore innovative far infrared therapy for dialysis patient care.
More Posts